Pharmaceutical Pricing and Reimbursement Policies in Canada:
This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada's achievements in meeting a range of objectiv...
Gespeichert in:
1. Verfasser: | |
---|---|
Weitere Verfasser: | |
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Paris
OECD Publishing
2006
|
Schriftenreihe: | OECD Health Working Papers
no.24 |
Schlagworte: | |
Online-Zugang: | Volltext |
Zusammenfassung: | This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada's achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada's prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high... |
Beschreibung: | 1 Online-Ressource (90 p.) 21 x 29.7cm. |
DOI: | 10.1787/346071162287 |
Internformat
MARC
LEADER | 00000cam a22000002 4500 | ||
---|---|---|---|
001 | ZDB-13-SOC-061316555 | ||
003 | DE-627-1 | ||
005 | 20231204121538.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210204s2006 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1787/346071162287 |2 doi | |
035 | |a (DE-627-1)061316555 | ||
035 | |a (DE-599)KEP061316555 | ||
035 | |a (FR-PaOEC)346071162287 | ||
035 | |a (EBP)061316555 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
084 | |a I11 |2 jelc | ||
084 | |a I18 |2 jelc | ||
100 | 1 | |a Paris, Valérie |e VerfasserIn |4 aut | |
245 | 1 | 0 | |a Pharmaceutical Pricing and Reimbursement Policies in Canada |c Valérie, Paris and Elizabeth, Docteur |
264 | 1 | |a Paris |b OECD Publishing |c 2006 | |
300 | |a 1 Online-Ressource (90 p.) |c 21 x 29.7cm. | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
490 | 0 | |a OECD Health Working Papers |v no.24 | |
520 | |a This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada's achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada's prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high... | ||
650 | 4 | |a Social Issues/Migration/Health | |
650 | 4 | |a Canada | |
700 | 1 | |a Docteur, Elizabeth |e MitwirkendeR |4 ctb | |
856 | 4 | 0 | |l FWS01 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/346071162287 |3 Volltext |
912 | |a ZDB-13-SOC | ||
912 | |a ZDB-13-SOC | ||
951 | |a BO | ||
912 | |a ZDB-13-SOC | ||
049 | |a DE-863 |
Datensatz im Suchindex
DE-BY-FWS_katkey | ZDB-13-SOC-061316555 |
---|---|
_version_ | 1804748648163049472 |
adam_text | |
any_adam_object | |
author | Paris, Valérie |
author2 | Docteur, Elizabeth |
author2_role | ctb |
author2_variant | e d ed |
author_facet | Paris, Valérie Docteur, Elizabeth |
author_role | aut |
author_sort | Paris, Valérie |
author_variant | v p vp |
building | Verbundindex |
bvnumber | localFWS |
collection | ZDB-13-SOC |
ctrlnum | (DE-627-1)061316555 (DE-599)KEP061316555 (FR-PaOEC)346071162287 (EBP)061316555 |
discipline | Wirtschaftswissenschaften |
doi_str_mv | 10.1787/346071162287 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01904cam a22003852 4500</leader><controlfield tag="001">ZDB-13-SOC-061316555</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20231204121538.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210204s2006 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/346071162287</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)061316555</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP061316555</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)346071162287</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBP)061316555</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I11</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I18</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Paris, Valérie</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical Pricing and Reimbursement Policies in Canada</subfield><subfield code="c">Valérie, Paris and Elizabeth, Docteur</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (90 p.)</subfield><subfield code="c">21 x 29.7cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.24</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada's achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada's prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high...</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Canada</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Docteur, Elizabeth</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/346071162287</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
id | ZDB-13-SOC-061316555 |
illustrated | Not Illustrated |
indexdate | 2024-07-16T15:07:13Z |
institution | BVB |
language | English |
open_access_boolean | |
owner | DE-863 DE-BY-FWS |
owner_facet | DE-863 DE-BY-FWS |
physical | 1 Online-Ressource (90 p.) 21 x 29.7cm. |
psigel | ZDB-13-SOC |
publishDate | 2006 |
publishDateSearch | 2006 |
publishDateSort | 2006 |
publisher | OECD Publishing |
record_format | marc |
series2 | OECD Health Working Papers |
spelling | Paris, Valérie VerfasserIn aut Pharmaceutical Pricing and Reimbursement Policies in Canada Valérie, Paris and Elizabeth, Docteur Paris OECD Publishing 2006 1 Online-Ressource (90 p.) 21 x 29.7cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Health Working Papers no.24 This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada's achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada's prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high... Social Issues/Migration/Health Canada Docteur, Elizabeth MitwirkendeR ctb FWS01 ZDB-13-SOC FWS_PDA_SOC https://doi.org/10.1787/346071162287 Volltext |
spellingShingle | Paris, Valérie Pharmaceutical Pricing and Reimbursement Policies in Canada Social Issues/Migration/Health Canada |
title | Pharmaceutical Pricing and Reimbursement Policies in Canada |
title_auth | Pharmaceutical Pricing and Reimbursement Policies in Canada |
title_exact_search | Pharmaceutical Pricing and Reimbursement Policies in Canada |
title_full | Pharmaceutical Pricing and Reimbursement Policies in Canada Valérie, Paris and Elizabeth, Docteur |
title_fullStr | Pharmaceutical Pricing and Reimbursement Policies in Canada Valérie, Paris and Elizabeth, Docteur |
title_full_unstemmed | Pharmaceutical Pricing and Reimbursement Policies in Canada Valérie, Paris and Elizabeth, Docteur |
title_short | Pharmaceutical Pricing and Reimbursement Policies in Canada |
title_sort | pharmaceutical pricing and reimbursement policies in canada |
topic | Social Issues/Migration/Health Canada |
topic_facet | Social Issues/Migration/Health Canada |
url | https://doi.org/10.1787/346071162287 |
work_keys_str_mv | AT parisvalerie pharmaceuticalpricingandreimbursementpoliciesincanada AT docteurelizabeth pharmaceuticalpricingandreimbursementpoliciesincanada |